{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:26:38Z","timestamp":1793622398444,"version":"4.5.0"},"reference-count":61,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2026,11,2]]},"DOI":"10.1080\/14737175.2026.2744754","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:35:19Z","timestamp":1791473719000},"page":"1053-1063","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["DT120 (MM120): a single-dose orally disintegrating formulation of lysergide tartrate for generalized anxiety disorder"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-8454","authenticated-orcid":false,"given":"Wies\u0142aw J.","family":"Cuba\u0142a","sequence":"first","affiliation":[{"name":"Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787"},{"key":"e_1_3_5_4_1","volume-title":"International classification of diseases, 11th revision (ICD-11)","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. International classification of diseases, 11th revision (ICD-11). Geneva: World Health Organization; 2022."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2211767"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1491966"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710001434"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012942.pub2"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/16506073.2018.1560358"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2020.11.326"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21177"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13481"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107076996"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852926101059"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852925100758"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2057"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00883-6"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3726"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyac075"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2008.00059.x"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.86"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35082"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2884"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01389-z"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12818"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.05.022"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0513-9"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.11.015"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13918"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15887"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/NMD.0000000000000113"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.08.025"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2024.99"},{"key":"e_1_3_5_34_1","unstructured":"Definium Therapeutics Inc. A study of MM120 for the treatment of generalized anxiety disorder. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2026 Jul 31]. Available from: http:\/\/clinicaltrials.gov\/show\/NCT05407064 NLM Identifier: NCT05407064."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00344.x"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6052"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.10869"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2024_534"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110402"},{"key":"e_1_3_5_41_1","unstructured":"Definium Therapeutics Inc. A phase 3 trial of MM120 for generalized anxiety disorder (Voyage). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2026 Jul 31]. Available from: http:\/\/clinicaltrials.gov\/show\/NCT06741228 NLM Identifier: NCT06741228."},{"key":"e_1_3_5_42_1","unstructured":"Definium Therapeutics Inc. A phase 3 trial of MM120 for generalized anxiety disorder (Panorama). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2026 Jul 31]. Available from: http:\/\/clinicaltrials.gov\/show\/NCT06809595 NLM Identifier: NCT06741228."},{"key":"e_1_3_5_43_1","unstructured":"Definium Therapeutics Inc. Quarterly report for the period ended 31 March 2026 (Form 10-Q). Washington (DC): US Securities and Exchange Commission; 2026."},{"key":"e_1_3_5_44_1","volume-title":"DT120 ODT clinical advancements and commercial strategy: investor and analyst day","author":"Definium Therapeutics","year":"2026","unstructured":"Definium Therapeutics. DT120 ODT clinical advancements and commercial strategy: investor and analyst day. NY: Definium Therapeutics; 2026. https:\/\/ir.definiumtx.com\/news-events\/press-releases\/detail\/223\/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day"},{"key":"e_1_3_5_45_1","volume-title":"Positive topline results from phase 3 Voyage study of DT120 ODT in generalized anxiety disorder","author":"Definium Therapeutics","year":"2026","unstructured":"Definium Therapeutics. Positive topline results from phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. 2026. Press release. https:\/\/ir.definiumtx.com\/news-events\/press-releases\/detail\/243\/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder"},{"key":"e_1_3_5_46_1","volume-title":"Positive topline results from phase 3 Panorama study of DT120 ODT in generalized anxiety disorder","author":"Definium Therapeutics","year":"2026","unstructured":"Definium Therapeutics. Positive topline results from phase 3 Panorama study of DT120 ODT in generalized anxiety disorder. 2026. Press release. https:\/\/ir.definiumtx.com\/news-events\/press-releases\/detail\/251\/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder"},{"key":"e_1_3_5_47_1","volume-title":"Positive topline results from the phase 3 Emerge study of DT120 ODT in major depressive disorder","author":"Definium Therapeutics","year":"2026","unstructured":"Definium Therapeutics. Positive topline results from the phase 3 Emerge study of DT120 ODT in major depressive disorder. 2026. Press release. https:\/\/ir.definiumtx.com\/news-events\/press-releases\/detail\/232\/definium-therapeutics-announces-positive-topline-results-from-phase-3-emerge-study-of-dt120-orally-disintegrating-tablet-odt-in-major-depressive-disorder"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05978-6"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010035"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.2546"},{"key":"e_1_3_5_52_1","volume-title":"Final Guidance for Industry","author":"US Food and Drug Administration","year":"2026","unstructured":"US Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations. In: Final Guidance for Industry. Silver Spring (MD): FDA; 2026."},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231211219"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2024.2445016"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3618"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1933434"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2024.02.004"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253261470523"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2003.10.016"},{"key":"e_1_3_5_60_1","unstructured":"Definium Therapeutics Inc. Annual report for the year ended 31 December 2025 (Form 10-K). Washington (DC): US Securities and Exchange Commission; 2026."},{"key":"e_1_3_5_61_1","volume-title":"Drug Scheduling: Schedule I substances","author":"US Drug Enforcement Administration","year":"2026","unstructured":"US Drug Enforcement Administration. Drug Scheduling: Schedule I substances. Washington (DC): DEA; 2026."},{"key":"e_1_3_5_62_1","volume-title":"Guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder. CPMP\/EWP\/4284\/02","author":"European Medicines Agency","year":"2005","unstructured":"European Medicines Agency. Guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder. CPMP\/EWP\/4284\/02. London: EMA; 2005."},{"key":"e_1_3_5_63_1","volume-title":"Assessment of Abuse Potential of Drugs: Guidance for Industry","author":"US Food and Drug Administration","year":"2017","unstructured":"US Food and Drug Administration. Assessment of Abuse Potential of Drugs: Guidance for Industry. Silver Spring (MD): FDA; 2017."}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2026.2744754","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737175.2026.2744754","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2026.2744754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:39:39Z","timestamp":1793619579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2026.2744754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,2]]}},"alternative-id":["10.1080\/14737175.2026.2744754"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2026.2744754","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}